Macrocyclic compounds as proteasome inhibitors
US11834515B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 11, 2018 |
| Grant date | Dec 5, 2023 |
| Priority date | — |
| Expiry date | Oct 11, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The compounds of the present invention are represented by the following compounds having Formula I and Formula (I′): where the substituents R1, R2, R2′, R3, R4, R5, R′, R″, X, Y, and Z are as defined herein and where the substituents R1, R2, R3, R4, R5, R′, R″, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.